In the genitourinary tract four kidney and five bladdertumors were found.
2
Twenty-one patients with bladdertumors were treated with THP instillation into the bladder.
3
Methods: A tissue array of 88 bladdertumors was assembled.
4
It could be a reliable tool in the evaluation of patients with bladdertumors.
5
Background: The noninvasive identification of bladdertumors may improve disease control and prevent disease progression.
6
Conclusions: The pooled OR value showed a moderate relationship between viral infection and bladdertumors.
7
TXAS was among the genes we identified based on its overexpression in invasive bladdertumors.
8
We think that the use of chemotherapy must be avoided in this low grade bladdertumors.
9
It was concluded that THP is a useful drug for the intravesical chemotherapy of bladdertumors.
10
Objectives: To identify the relationships between key components of the proliferative and apoptotic pathways in bladdertumors.
11
The data suggest that primary simultaneous urethrectomy should be performed in all patients undergoing cystoprostatectomy for multifocal bladdertumors.
12
Sixty patients with two or less, primary or recurrent papillary bladdertumors and a negative urinary cytology were planned.
13
The highest frequency of mutations was found for cervical cancer, followed by bladdertumors, breast cancer and endometrial neoplasia.
14
Purpose: In approximately 20% of patients with superficial bladdertumors, the tumors progress to invasive tumors after treatment.
15
Results: Supervised analysis of gene expression data revealed a gene expression signature that is strongly associated with invasive bladdertumors.
16
In the United States, over 51,000 new cases of urinary bladdertumors are diagnosed annually.